Sign in
Active, not recruitingPhase 2/3

A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women

Key facts

Who runs it
Minervax ApS
Where
Denmark and South Africa6 sites in 2 countriesChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 2/3
People taking part
137 people enrolled
Started
7 Mar 2025
Expected to end
30 Jun 2029
Type of study
Interventional, 3 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • GBS-NN/NN2 vaccine
Record updated
4 September 2026

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Can take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Participant living in Denmark or South Africa who has participated in Trial MVX0004 (NCT05154578) and has received at least 1 dose of the GBS-NN/NN2 vaccine
  • Participant who is able to read and understand and capable of giving personal signed informed consent
  • Participant who is willing and able to comply with scheduled visits, the investigational plan, and other trial procedures
  • Participant who is granting access to their trial-related medical records and to their trial materials from Trials MVX0004
  • Participant who is expected to be available for the duration of the trial and who can be contacted by telephone during trial participation

Who cannot take part

  • Participant who participated in other trials involving investigational drug(s) or devices within 28 days prior to trial entry, and/or are participating in other trials involving investigational drug(s) or devices at trial entry, or plan to (continue to) participate in other trials involving investigational drug(s) or devices during this trial
  • Participant with known or suspected immunodeficiency or cancer or a family history of congenital or hereditary immunodeficiency. Note: Human immunodeficiency virus (HIV) infection is not an exclusion criterion if HIV viral load is ≤1000 copies/mL and the participant has been on antiretroviral therapy for at least 3 months prior to screening and is clinically stable
  • Participant receiving chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to trial entry. An immunosuppressive dose of glucocorticoid will be defined as a systemic dose ≥10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted
  • Participant who received blood, blood products, plasma derivatives, or any immunoglobulin preparations in the 12 weeks prior to trial entry or is planning to receive such products during this trial
  • Participant who received any marketed or investigational GBS vaccines (other than GBS-NN/NN2 in the MVX0004 Trial) or who is planning to receive any marketed or investigational (other than GBS NN/NN2) GBS vaccines during this trial
  • Participant with confirmed Group B Streptococcus (GBS) infection since participation in Trial MVX0004
  • Participant with any psychiatric condition, including recent (within the past year) active suicidal ideation/behaviour that may increase the risk of trial participation or, in the investigator's judgement, make the participant unsuitable for participation in the trial
  • Participant with current or history of drug or alcohol abuse, as judged by the investigator
  • Any personnel involved in the conduct of the trial (and their family members), including, but not limited to, site staff members, MinervaX employees, and any vendor or contract research organisation (CRO) employees

Where is this trial?

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main objective of the study is to evaluate the persistence of the immunoglobulin G (IgG) antibody responses, specific to Alpha-like protein CN (AlpCN), Ribosomal Protein N (RibN), Alpha-like protein 1N (Alp1N), and Alpha-like protein 2 and 3 (Alp2-3N), after a primary vaccination with GBS-NN/NN2 in all participants.

The 3 groups in the trial

  • Non-Pregnant Participants: No GBS-NN/NN2 Booster DoseNo study treatment, for comparison

    Participants who received at least one dose of GBS-NN/NN2 during the parent trial (MVX0004) who do not become pregnant during this trial will not receive a GBS-NN/NN2 booster dose.

  • Pregnant Participants: GBS-NN/NN2 Booster DoseTreatment being tested

    Participants who received at least one dose of GBS-NN/NN2 during the parent trial (MVX0004) and, become pregnant during this trial, and qualify, will receive a GBS-NN/NN2 booster dose.

    Treatment: GBS-NN/NN2 vaccine

  • Pregnant Participants: No GBS-NN/NN2 Booster DoseNo study treatment, for comparison

    Participants who received at least one dose of GBS-NN/NN2 during the parent trial (MVX0004) and, become pregnant during this trial but do not qualify for receiving a GBS-NN/NN2 booster dose.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Follow-up Trial to Assess the Persistence of the Immune Response to the Group B Streptococcus Vaccine (GBS-NN/NN2) After a Primary Vaccination of Healthy Pregnant Women, and to Assess Safety, Reactogenicity, and Immunogenicity of the GBS-NN/NN2 Vaccine When Administered During Follow-Up as a 1 Booster Dose During a New Pregnancy
Record updated
4 September 2026